Federal Ministry of Research, Technology and Space (BMFTR)

Note: The project descriptions reflect the status and objectives of the projects at their initial stage.

DigiZell

Project duration: February 2026 – ongoing

Project goal: The treatment of aggressive cancers and immune deficiencies remains a major challenge in medicine. CAR T cell therapies, which use engineered immune cells, offer significant potential but are complex and time-consuming to manufacture. Continuous inline quality control is crucial for the safety and efficacy of these therapies. The project aims to develop a photonic cell analysis module that enables real-time monitoring during cell production and cell therapy as a stand-alone device. This supports the technological independence of Germany and the EU.

Approach: The photonic cell analysis module is designed to quickly record process parameters and provide inline quality control during CAR T cell manufacturing. As a stand-alone point-of-care device, it can also be used for immune monitoring and therapy control of immune deficiencies and blood cancer. A digital single-photon sensor chip, following pulsed laser excitation, extracts cell-specific signatures via the temporal decay curve of the fluorescence signal. This enables more precise adjustment of growth conditions and optimizes cell production as well as the detection of weak fluorescence signals from marker proteins on immune cells. The technology is integrated into a compact system using a 3D-printing process. This resulting system can be integrated as a module into a cell production device or used as a stand-alone point-of-care device, enabling immune monitoring directly at the patient's bedside without further time-consuming and error-prone sample processing.

More information: https://www.quantensysteme.info/projektatlas/projekte/q/digizell

Identifier: 13N17454

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DEDuisburgFraunhofer Institute for Microelectronic Circuits and Systems IMS
DEBerlinPicoQuant
DEMannheimLaboratory for Haematology Mannheim

ResCPa study

Response features, efficacy, and safety of CD318-targeted CAR-T cell therapy against pancreatic cancer

Project duration: December 2024 – ongoing

Project goal: Pancreatic ductal adenocarcinoma (PDAC) is a common cancer with poor prognosis and very little improvements in oncological therapies during the last decades, requiring innovative therapeutic [SH1] approaches. Therefore, Miltenyi Biotec has started a large preclinical research program on PDAC immunotherapy and identified that a CD318-directed chimeric antigen receptor (CAR) T cell therapy is highly effective against PDAC in preclinical cancer models without target-specific toxicities. Based on these findings, a German consortium composed of industry partner Miltenyi Biotec and of academic experts in cancer medicine and T-cell driven immunotherapies was founded to investigate CD318-CAR-T cell therapy in patients with metastatic or advanced PDAC refractory to standard-of-care in a phase I/IIa clinical study.

Approach: This research program coordinated by Christoph Stein-Thoeringer, University Clinic Tübingen, comprises three packages of translational research: First, we aim to optimize and validate a fully human CD318 CAR construct and, subsequently, we will manufacture a CAR-T cell product against PDAC. Second, we will perform a phase I/IIa clinical investigator-initiated trial (IIT) covering all work from preparation of study documents, regulatory approval, study subject recruitment, to treatment, and data analyses. Third, we aim to investigate mechanisms underlying efficacy or therapy resistance of CAR-T cell immunotherapy against PDAC by studying the tumor and immune microenvironment in these patients and in preclinical models.

More information: www.medizin.uni-tuebingen.de/de/rescpa-studie

Identifier: 01KD2421B

Project coordinator

CountryCityInstitution
DETübingenUniversity Hospital and Faculty of Medicine Tübingen

Project partner(s)

CountryCityInstitution
DEBerlinBerlin Institute for Medical Systems Biology & Max-Delbrück-Centrum Berlin
DEFreiburgMedical Center University of Freiburg
DEMunichTechnical University Munich
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

NK-Alliance

Ex vivo-modified natural killer cells for immunotherapy of tumors and autimmune diseases

Project duration: October 2024 – ongoing

Project goal: Our project aims to fully exploit the potential of natural killer (NK) cells to develop broadly applicable, cost-efficient, and effective NK cell therapies for the treatment of both tumor and autoimmune diseases, bringing them to clinical applications, and commercializing them in the future. The project focuses on solving current limitations in the translation of NK cells to the clinic in:

  • the area of genetic modification with chimeric antigen receptors (CARs)
  • ex vivo expansion to clinically relevant cell numbers of a tumor-reactive NK cell subtype or CAR-engineered-NK cells
  • translation to clinical application

The project is complemented by innovative research on the optimization of viral gene transfer systems and a novel in silico design for the optimization of CARs against identified tumor markers.

Approach: In its sub-project, Miltenyi Biotec will further develop ex vivo-modified NK cells for the immunotherapy of tumors and autoimmune diseases. First, it prepares the clinical translation of target-specific CAR NK cells for the treatment of acute myeloid leukemia (AML). This corresponds to work that builds directly on the first funding phase of the SaxoCell’s Cluster of Excellence. Second, it will establish a robust, automated small-scale manufacturing process to combine electroporation with lentiviral transduction. Additionally, in vivo experiments on the efficiency and toxicity of the improved CAR NK cells will be carried out.

More information: www.saxocell.de

Identifier: 03ZU2111DI

Project coordinator

CountryCityInstitution
DELeipzigFraunhofer Institute for Cell Therapy and Immunology

Project partner(s)

CountryCityInstitution
DELeipzigUniversity Hospital Leipzig
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

PerImmune

Intraperitoneal immune modulation for colorectal peritoneal metastases

Project duration: April 2023 – August 2026

Project goal: Peritoneal metastasis (PM) from colorectal cancer has a considerable clinical impact and a low response rate to immunotherapy – about 5%. Nevertheless, this topic has received little attention and considerable gaps in knowledge exist. To address this issue, the PerImmune consortium intends to characterize the immune contexture of colorectal peritoneal metastasis. It also aims to develop a potential new treatment option: modulation of the tumor immune microenvironment by intraperitoneal administration of immune modulators such as toll-like-receptor (TLR) agonists, either as a standalone treatment option, or in combination with immune checkpoint inhibitors (ICIs).

Approach: The PerImmune consortium is a multidisciplinary group that brings together highly complementary areas of expertise. The advanced technologies necessary for the characterization of the immune contexture of colorectal PM, like single cell RNA seq and spatial transcriptomics, are well established in their laboratories. To modulate the tumor immune microenvironment, the consortium will develop nanoparticles for oxaliplatin and TLR agonists. Their toxicity, biodistribution, and anticancer efficacy will also be tested in mouse models.

More information: www.transcan.eu

Identifier: 01KT2314

Project coordinator

CountryCityInstitution
BEGhentGhent University,
Department of Human Structure & Repair
Laboratory of Experimental Surgery

Project partner(s)

CountryCityInstitution
NOOsloOslo Universtiy Hospital,
Department of Gastroenterological Surgery
FRVilleurbanneUniversité Claude Bernard Lyon 1,
Laboratoire d`Automatique, de Génie des Procédes et de Génie Pharmaceutique
FRParisInstitut Gustave Roussy,
Department of Tumor Immunology and Immunotherapy of Cancer
TRMuglaMugla University,
Department of Bioinformatics
Graduate School of Natural and Applied Sciences
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

AdCAR-AML

Adapter CAR T cells for the treatment of patients with relapsed/refractory acute myeloid leukemia

Project duration: April 2023 – June 2025

Project goal: Within the AdCAR-AML project, the partners – LMU Munich, FAU Erlangen-Nuremberg and Miltenyi Biotec – aim to establish an adapter-based Chimeric Antigen Receptor (CAR) T cell platform that provides AML patients with personalized T cell based immunotherapy that has a high safety profile for a wide range of target antigens. Although CD19-CAR T cells have been approved for patients with relapsed/refractory (r/r) B cell malignancies, application of this therapy to myeloid malignancies has been hampered by the lack of suitable, safely targetable antigens on AML cells.

Approach: Under the project funding, the partners will conduct preclinical testing of the AdCAR T platform and initiate a first-in-human proof-of-concept phase I clinical trial to evaluate the feasibility and tolerability of CD33 AdCAR T cells in patients with r/r AML. The study will be the basis for implementing flexible combinatorial AdCAR T therapeutic approaches to treat AML in the future.

Identifier: 01EN2307B

More information: www.gesundheitsforschung-bmbf.de

Project coordinator

CountryCityInstitution
DEMunichLMU Klinikum
Medizinische Klinik und Poliklinik III

Project partner(s)

CountryCityInstitution
DEErlangenFriedrich-Alexander-Universität
Erlangen-Nürnberg
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

QEED

Quantum light for a new imaging technique for early and differentiated recognition of biomarkers in personalized medicine

Project duration: January 2023 – ongoing

Project goal: Cancer is the second leading cause of death in Western societies. Since it cannot be prevented, early and differentiated detection is extremely important for rapid intervention and cure. It has already been shown that mid-infrared radiation (MIR) allows tumor cells to be detected with the highest reliability, but current measurement times are far too long for rapid diagnostic use. The QEED project aims to develop a new imaging technique that significantly reduces measurement time. Combined with a simple, label-free sample preparation, this new QEED (Quantum‐Enhanced Early Diagnostics) microscopy should enable a high sample throughput and thus, for the first time, integration into clinical workflows.

Approach: The QEED consortium combines the expertise of three research institutes, two clinical institutes, and five industrial partners. The group will develop a new quantum entanglement-based imaging technique that transfers clinically-relevant information measured in the MIR spectral range to near-infrared (NIR), which can be detected reliably and rather quickly. This will be used for the label-free early detection of cancer cells in biopsy samples. Based on innovative ultra‐bright photon pair sources and their adapted measurement and analysis, different demonstrators are planned – for scientific (biomedical) research, and with an integrated fluorescence unit for automated pathology in clinical routine.

More information: www.quantentechnologien.de

Identifier: 13N16378

Project coordinator

CountryCityInstitution
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

Project partner(s)

CountryCityInstitution
DEWendelsteinSill Optics GmbH
DEBerlinart photonics GmbH - Member of the Nynomic Group
DEBerlinFerdinand-Braun-Institut gGmbH
Leibniz-Institut für Höchstfrequenztechnik
DEMarburgSacher Lasertechnik GmbH
DEMunichFraunhofer-Institut für Lasertechnik ILT
DEBerlinHumboldt-Universität zu Berlin
Institut für Physik
DEBochumRuhr-Universität Bochum,
Zentrum für Proteindiagnostik (PRODI)
DEBerlinCharité-Univeristätsmedizin Berlin, Experimental and Clinical Research Center (ECRC)
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

TACTiC

Tailored application for individualized cell therapy with iPSC-derived cardiomyocytes – Preclinical evaluation in a non-human primate model and a roadmap for clinical application

Project duration: July 2022 – June 2025

Project goal: The options for treating patients suffering from heart failure due to severe myocardial infarction and ischemic cardiomyopathies are currently limited to heart transplantation or left ventricular assist device (LVAD) implantation. Patient derived induced pluripotent stem cells (iPSCs) are considered a potential innovative therapeutic option for heart repair. These cells offer the chance to generate new heart muscles. The TACTiC consortium aims to set up a clinical protocol for the application of autologous human iPSC-derived cardiomyocyte-based heart repair in patients suffering from ischemic cardiomyopathy after myocardial infarction.

Approach: The TACTiC consortium brings together the expertise and cutting-edge technologies needed to facilitate clinical translation and perform a proof of concept for the efficacy of this new therapeutic concept. In this project, the current approach for applying the iPSC-derived cardiomyocytes will be adapted and further improved. To characterize and quantify graft formation and explore potential therapeutic risks, novel whole-organ imaging technologies will be used, leading to a therapy that is safe, personalized, and efficient.

More information: www.gesundheitsforschung-bmbf.de

Identifier: 01EK2108C

Project coordinator

CountryCityInstitution
DEHannoverMedizinische Hochschule Hannover

Project partner(s)

CountryCityInstitution
DEGöttingenDeutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung
DEGarbsenLeibniz Universität Hannover, Fakultät für Maschinenbau, Institut für Mechatronische Systeme
DEHannoverFraunhofer-Institut für Toxikologie und Experimentelle Medizin (ITEM)
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

SaxoCell - CAR-NK 4.0

Platform for automated production of allogeneic CAR-NK cell cancer therapeutics

Project duration: October 2021 – October 2024

Project goal: The CAR-NK 4.0 project is one of 12 different projects integrated into the SaxoCell Cluster in Saxonia. This cluster aims to develop highly efficient and affordable Advanced Therapy Medicinal Products (ATMPs). In this context, the CAR-NK 4.0 project focuses on the challenges of producing ATMPs at industrial scale and increasing their efficacy.

Approach: The CAR-NK 4.0 project will develop a platform mediated by artificial intelligence and with an autonomous and fully automated manufacturing process. Ultimately, this platform will be used to enable an allogenic and target-specific CAR NK proof-of-concept study for the treatment of myeloid neoplasms. Furthermore, the project aims to improve the therapeutic efficacy of CAR NK cell therapy by implementing cutting-edge technologies like bi-specific CARs.

More information
www.bmbf.de
www.saxocell.de

Identifier: 03ZU1111CD

Project coordinator

CountryCityInstitution
DELeipzigFraunhofer Institut für Zelltherapie und Immunologie IZI

Project partner(s)

CountryCityInstitution
DEChemnitzKlinikum Chemnitz gGmbH
DELeipzigUniversität und Universitätsmedizin Leipzig
DEHeidelbergAffimed GmbH
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

IMAGINE

Fighting cancer with optimal personalized immunotherapies

Project duration: October 2021 – September 2025

Project goal: CAR T cell immunotherapies are a promising treatment option for hematologic tumors. These therapies incorporate the patient’s own T cells, which have been genetically altered to recognize and destroy tumor cells. In order to accurately design a CAR therapy to target a specific tumor, precise identification of target molecules on tumor cells and CAR T cells is required. Unfortunately, classical detection methods available in clinical practice are not sensitive enough to identify these molecules. To overcome this gap, the IMAGINE consortium aims to develop an innovative super-resolution imaging platform that can identify tumor antigens and CAR T receptors, facilitating the creation of highly specific, personalized therapies for cancer patients.

Approach: IMAGINE will research and develop an automated super-resolution microscopy platform. The imaging platform will enable clinicians to routinely perform automated and sensitive high throughput screening for tumor-associated antigens. Additionally, the platform will be able to characterize tumor-reactive CAR T cells with molecular precision, significantly improving the specificity and efficacy of cancer treatment.

More information: www.photonikforschung.de

Identifier: 13N15988

Project coordinator

CountryCityInstitution
DEWürzburgJulius-Maximilians-Universität Würzburg

Project partner(s)

CountryCityInstitution
DEWürzburgUniversitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II
DEMartinsriedMax-Planck-Institut für Biochemie
DEGräfingenMassive Photonics GmbH
DEWürzburgT-CURX GmbH
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

OptiCAN

Optimized T cells for personalized immunotherapy for solid tumors

Project duration: May 2021 – April 2024

Project goal: The aim of OptiCAN is to expand the therapeutic applications of CAR T cell therapies, which are currently limited. The consortium will use advanced genetic engineering of patient-derived T cells to extend their application towards personalized immunotherapy. Pancreatic cancer and melanoma will be used as model indications. This will pave the way to bring these optimized T cell products into clinical application and make personalized medicines accessible for large patient groups.

Approach: Within OptiCAN, several innovative approaches for functional improvement of T cells will be tested. The first step involves defining the best starting cell population for generating effective T cell products. In the second step, novel, more efficient methods for the functional improvement of the T cell product will be determined through pioneering CAR technologies. Functionality and efficacy of the generated cell products will be validated in preclinical animal and advanced ex vivo models. Project results will be integrated into Miltenyi Biotec’s CliniMACS Prodigy® platform, which allows highly efficient automated GMP-compliant manufacturing of CAR T cell products directly at the point-of-care.

More information: www.gesundheitsforschung-bmbf.de

Identifier: 01KU2103

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DEMunichKlinikum der Ludwig-Maximilian-Universität München, Onkologie- Medizinische Klinik und Poliklinik III
SEGothenburgSahlgrenska Center for Cancer Research at University of Gothenburg
FRParisInstitut Cochin, Université Paris Descartes

GD2-IL18 CART

Phase I clinical trial of safety, dose-finding, and feasibility of adoptive T cell therapy with GD2-IL18 CART in patients with relapsed or refractory GD2-positive solid tumors

Project duration: November 2020 – ongoing

Project goal: CAR T cell therapy is an effective treatment modality in hematologic malignancies, but solid tumors are often refractory to it. One possible approach to treating solid tumors would be to use GD2-IL18 CART, namely CAR T cells that release interleukin 18 (IL18) which is an immune-activating cytokine that greatly increases the cells’ activity against cancer. The GD2-IL18 consortium aims to conduct a first-in-human phase I multi-center clinical trial in patients with advanced, previously incurable cancers. The study is intended to test and confirm the safety of this treatment’s application.

Approach: The consortium will use cytokine-enhanced CAR T cells, produced in Miltenyi Biotec’s CliniMACS Prodigy®, that target the cell-surface ganglioside GD2, a common expression of solid tumors including advanced breast cancer, Ewing’s sarcomas, osteosarcomas, and neuroblastomas. Previous clinical trials have already confirmed the safety of GD2-directed CAR T cell therapies. Here, GD2-specific CARs will be augmented with an inducible transgene encoding for the IL18 cytokine to increase CAR T cell activity in the local tumor microenvironment.

More information: www.gesundheitsforschung-bmbf.de

Identifier: 01EN2007E

Project coordinator

CountryCityInstitution
DEMünsterUniversity of Münster, Department of Pediatric Hematology and Oncology

Project partner(s)

CountryCityInstitution
DEErlangenUniversitätsklinikum Erlangen
DERegensburgUniversitätsklinikum Regensburg, Leibniz-Institut für Immuntherapie (LIT)
DEHannoverHannover Medical School, Institute of Experimental Hematology
DEBonnHaus der Krebs-Selbsthilfe Bundesverband e.V.
DEBonnDeutsche Kinderkrebsstiftung
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

AspecT NMO

Measuring autoantigen-specific T cells as new diagnostic sensors and therapeutic targets in neuromyelitis optica

Project duration: June 2020 – December 2023

Project goal: Neuromyelitis optica spectrum disorders (NMOSD) form a rare group of severe antibody mediated autoimmune diseases (AIDs) of the central nervous system. The NMOSD aetiology is yet unknown, but it often affects the optic nerve and can also affect other areas of the nervous system responsible for motor, sensory, and autonomic functions. The disease requires lifelong suppression of the immune system, which has potentially severe side effects. AspecT NMO will deliver a pioneering contribution to understanding human AIDs by characterizing the autoreactive lymphocytes in NMOSD that are centrally involved in disease pathogenesis and chronification. This work will provide the basis for the improved diagnosis, prognosis, and treatment of the disease.

Approach: The AspecT NMO consortium brings together multidisciplinary, internationally renowned researchers who have developed powerful technologies allowing for the molecular and functional characterization of autoreactive T cells and their interaction with B cells. Integrating Miltenyi Biotec will catalyze the development of optimized analysis tools for rapid application in basic research and clinical routines.

More information: www.gesundheitsforschung-bmbf.de

Identifier: 01GM1923B

Partner coordinator

CountryCityInstitution
DEKielUniversitätsklinikum Schleswig-Holstein & Christian-Albrechts-Universität (CAU),
Institute of Immunology

Project partner(s)

CountryCityInstitution
CHZurichUniversity of Zurich (UniZu),
Neuroimmunology and MS Research, Department of Neurology
FRLyonLyon University Hospital (HCL),
National Referral Centre for Rare Inflammatory Disorders of the Brain and the Spinal Cord
FRParisInstitut National de la Santé et de la Récherche Médical (INSERM),
Institut Necker-Enfants Malades
ILRehovotWeizmann Institute of Science (Weiz),
Immunology Department
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

iPStemRNA

Generation of GMP-compliant induced pluripotent stem cells from universal donors

Project duration: May 2017 – October 2023

Project goal: Given the tissue properties of the differentiated progeny of human induced pluripotent stem cells (iPSCs), the potential for clinical exploitation is extraordinary. Clinical translation is, however, a complex process. It involves numerous steps of process development, quality control tests, validation, and intensive communication with regulatory agencies. The iPStemRNA consortium proposes developing a novel GMP-compliant process to produce human iPSC lines with utmost patient safety considerations in mind. It will optimize the purity and genomic stability of generated lines, as well as the differentiation potency assays that are required by regulatory authorities to clinically approve them.

Approach: Within this consortium, the Miltenyi Group will produce GMP-grade mRNAs for clinical reprogramming of human fibroblasts. The ultimate objective of the project is to produce GMP-grade human iPSC lines. To achieve this, Miltenyi Biotec will build on their RNA-based technology for reprogramming adult cells to develop a new mmRNA (modified messenger RNA) manufacturing process that is compliant with GMP standards. This production process will employ controlled methods and traceable animal-component-free materials. The consortium will also be provided with qualified GMP-grade high quality transfection reagents and media optimized to mmRNA reprogramming.

More information: www.gesundheitsforschung-bmbf.de

Identifier: 01EK1610C

Project coordinator

CountryCityInstitution
DEMunichHelmholtz Zentrum München,
Institut für Stammzellforschung

Project partner(s)

CountryCityInstitution
DEDresdenTechnische Universität Dresden,
Institut für experimentelle Transfusionsmedizin
DEBerlinMax-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft,
BIH Core Facility Stem Cells
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

ELICIT

Advanced light sheet microscopy for high-throughput clinical analysis of immune cell infiltration of tumor samples

Project duration: May 2017 – April 2020

Project goal: The aim of the joint project was to develop a novel, compact and easy-to-use confocal laser scanning light sheet microscope for routine use in clinical and research applications in combination with innovative optical probes as a photonic system solution.

Approach: Whole tumor samples with a volume of up to 1 cm3 were imaged i) in a complex and three-dimensional (3D) manner, ii) with selective and sensitive cell staining, iii) with cellular resolution, iv) in a short time and v) for the first time in an automated manner with high throughput. Imaging of immune cells and their interaction with tumor and stroma were realized using multiple fluorescently labeled antibodies in the same sample (multiplexing). The envisaged automation of the ELICIT platform accelerated the throughput of samples and the time required for diagnosis, reduced the amount of sample material needed, and enabled an increase in complex information, which opened up new perspectives for diagnosis, therapy strategy, stratification of patients and their prognosis.

More information: www.photonikforschung.de

Identifier: 13N14346

Project coordinator

CountryCityInstitution
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

Project partner(s)

CountryCityInstitution
DEGöttingenUniversitätsmedizin Göttingen (UMG)
DEGöttingenMax-Planck-Institut für multidisziplinäre Naturwissenschaften
DEPenzbergRoche Diagnostics GmbH

FEMSCOPY

High-speed 2-photon microscopy using a novel fs light source for brain imaging

Project duration: June 2016 – September 2018

Project goal: The human brain remains one of the greatest mysteries in science and one of the greatest challenges in medicine. Brain imaging with the help of the opto-genetics toolbox is revolutionizing our understanding of the brain network. Still, the current technology was not providing what was needed - monitoring networks of several 100 neurons at sub-cellular resolution at video-rate. Thus the intended products promised to be a market success and will ultimately also help medical research in general.

Approach: We aimed to create an exceptional laser and microscopy tool tailored for the needs of the brain imaging community. LC delivered a novel wavelength-tunable femtosecond light source. IPHT delivered a 2-photon structured spotlight-illumination (2P-SIM) super-resolution microscopy setup. LaVision BioTec* delivered a novel modular scan head and integrated the laser source, 2P-SIM setup and scan head into LaVision BioTec's* microscope system. JGU validated the tool and applied it to brain imaging experiments.

More information: www.kooperation-international.de

Identifier: 01QE1630B

Partner coordinator

CountryCityInstitution
LTVilniusLight Conversion (LC)

Project partner(s)

CountryCityInstitution
DEJenaLeibniz Institut für Photonische Technologien (IPHT)
DEMainzUniversitätsmedizin der Johannes Gutenberg-Universität Mainz (JGU)
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

CD20 CAR-TIME

CD20 CAR transduced T cells for individualized melanoma therapy

Project duration: December 2015 – December 2023

Project goal: Of the 17,000 patients diagnosed with malignant melanoma in Germany every year, 3,000 die as a consequence of the disease. Conventional therapy options such as dissection, chemotherapy, and radiotherapy show only limited success and are often accompanied by severe adverse reactions. Recently, many success stories in cancer therapy were reported using CAR T cell therapy. This project will explore the application of this innovative therapy to treat melanoma.

Approach: Recent findings have indicated that the CD20 marker expressed on melanoma cancer stem cells might be an effective target. Therefore, CAR T cells will be applied to treat melanoma patients in a clinical study. This project consortium will also explore how automation can make this personalized form of therapy available to a large number of patients.

More information
www.gesundheitsforschung-bmbf.de
www.cd20-car-time.de

Identifier: 01EK1507A

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DEHannoverMedizinische Hochschule Hannover (MHH), Institut für Zelltherapeutika der MHH (IZT)
DERegensburgUniversitätsklinikum Regensburg, Leibniz-Institut für Immuntherapie (LIT)

TOMOSphere

Tomographic monitoring of 3D cell cultures from pluripotent stem cells

Project duration: July 2013 – January 2017

Project goal: In successful therapies, stem cells are often applied empirically and without precise knowledge of their molecular function. In order to enable a decisive progress in therapeutic concepts, research into the respective fundamentals must therefore be advanced a priori. This includes in particular the understanding of the physiology of stem cells, such as their pluripotency, cell differentiation, metabolic activity and cell cycle activity.

Approach: The motivation of the consortium was illustrated by the strategy to 1.) implement a time- and location-resolved monitoring of human iPS cell aggregates by non-invasive qualitative and quantitative assessment of the aggregates with respect to their structure, integrity, homo- and heterogeneity, cell density, pluripotency and degree of differentiation, 2. ) to implement the technical realization of the methods under 1.) into a high-throughput process, and 3.) as an overall goal, to apply 1.) and 2.) for process development and monitoring of large-scale production of pluripotent stem cells in stirred industry-relevant bioreactor systems in suspension culture. The concept described here leads to the development of new technologies that are critical to fully exploit the potential of stem cells in regenerative medicine and the pharmaceutical industry. This could result in a sustainable shift of currently existing therapeutic boundaries.

More information: www.photonikforschung.de

Identifier: 13N12604

Project coordinator

CountryCityInstitution
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

Project partner(s)

CountryCityInstitution
DEHannoverLaser Zentrum Hannover e.V. (LHZ),
Institut für Zelltherapeutika der MHH (IZT)
DEHannoverMedizinische Hochschule Hannover –
Leibniz Forschungslaboratorien für Biotechnologie und künstliche Organe (LEBAO)
DEGöttingenScivis wissenschaftliche
Bildverarbeitung GmbH
DEWendelsteinSill Optics GmbH & Co. KG

*LaVision BioTec was acquired by Miltenyi Biotec in 2018. As of September 2023, LaVision BioTec GmbH is operating as Miltenyi Biotec B.V. & Co. KG

Partner with us

Are you looking for a reliable partner for your next grant project?

Get in touch with our Grant Management Team to discuss your ideas.

You have previously chosen International as your location.
What do you want to do?